From the Research
Difference between Prolia (denosumab) and Jubbonti
- Prolia (denosumab) is a human recombinant monoclonal antibody that is approved for the treatment of postmenopausal osteoporosis in women at high or increased risk of fracture 1, 2, 3.
- Jubbonti is a biosimilar to reference denosumab (Prolia/Xgeva), approved by the US FDA, EMA, and Health Canada for all indications of reference denosumab 4.
Key Similarities and Differences
- Both Prolia (denosumab) and Jubbonti (SDZ-deno) have the same mechanism of action, binding to receptor activator of nuclear factor κB ligand and inhibiting bone resorption 1, 4.
- Clinical evaluation has shown that SDZ-deno (Jubbonti) is similar to REF-deno (Prolia) in pharmacokinetics and pharmacodynamics, and is effective in postmenopausal women with osteoporosis 4.
- The main difference between Prolia (denosumab) and Jubbonti is that Jubbonti is a biosimilar, which means it is a biological product that is highly similar to an already approved biological product (in this case, Prolia) 4.
Efficacy and Safety
- Studies have shown that denosumab (Prolia) is effective in reducing the risk of vertebral, nonvertebral, and hip fractures, and increasing bone mineral density in postmenopausal women with osteoporosis 1, 2, 3.
- Jubbonti (SDZ-deno) has been shown to be similar in efficacy to REF-deno (Prolia) in postmenopausal women with osteoporosis, with a similar safety profile 4.
- A systematic review and meta-analysis found that denosumab was more effective in increasing bone mineral density compared to other treatments, but had a similar safety profile 5.